[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571533":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":40,"locations":49,"responsibleParty":68,"collaborators":70,"id":74,"slug":27,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":27,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":27,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":27,"overallStatus":52,"whyStopped":27,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Clear Scientific, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Participants receive methamphetamine HCl (30 mg) followed by placebo (saline).",[13,14],"Drug: Methamphetamine","Drug: Sterile Saline",{"label":16,"type":17,"description":18,"interventionNames":19},"Active","ACTIVE_COMPARATOR","Participants receive methamphetamine HCl (30 mg) followed by one of four doses of CS-1103",[13,20],"Drug: CS-1103",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Methamphetamine","Methamphetamine HCl for intravenous administration",[16,9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Sterile Saline","Sterile Saline for intravenous administration",[9],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"CS-1103","CS-1103 for intravenous administration",[16],[37],{"name":38,"affiliation":5,"role":39},"Xinhua Li, Ph.D.","PRINCIPAL_INVESTIGATOR",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":27,"email":45},"Anna Del Rosario, B.S.","CONTACT","617-621-8500","adelrosario@clearsci.com",{"name":47,"role":43,"phone":44,"phoneExt":27,"email":48},"Piercen Oliver, Ph.D.","poliver@clearsci.com",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"California Clinical Trials Medical Group","RECRUITING","Glendale","California","91206","United States",{"type":58,"coordinates":59},"Point",[60,61],-118.25508,34.14251,{"lat":61,"lon":60},[64],{"name":65,"role":43,"phone":66,"phoneExt":27,"email":67},"Lev Gertsik, M.D.","888-228-7425","study.losangeles@parexel.com",{"type":69,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[71],{"name":72,"class":73},"National Institute on Drug Abuse (NIDA)","NIH","100571533",false,"NCT06721494","A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine","A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine","Major Inclusion Criteria:\n\n1. Healthy participants aged 18 to 55 years, inclusive;\n2. Meets DSM-5 criteria for methamphetamine use disorder;\n3. Not seeking treatment for methamphetamine use disorder;\n4. Primary route of methamphetamine self-administration must be intravenous or smoking;\n5. Able to abstain from methamphetamine without experiencing severe withdrawal;\n6. A body mass index between 18 to 30 kg\u002Fm2, inclusive and a minimum body weight of 50 kg;\n7. Females must not be lactating and must have a negative pregnancy test during screening and admission.\n\nMajor Exclusion Criteria:\n\n1. Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2;\n2. History of cardiovascular disease;\n3. Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;\n4. History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.","ALL","18 Years","55 Years",{"count":84,"type":85},40,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).",[91,92,93],"Methamphetamine Intoxication","Methamphetamine Disorders","Methamphetamine Abuse","2026-01-09",{"date":96,"type":97},"2026-01-12","ACTUAL",{"date":99,"type":85},"2026-02-05",{"date":101,"type":85},"2026-09-11",{"name":5,"class":6},1]